Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 3Triple Negative Metastatic Breast Cancer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Primary Breast Cancer 1Peritoneal Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

Paclitaxel 26pembrolizumab 24Docetaxel 20Capecitabine 19Fulvestrant 17Trastuzumab 16Anastrozole 15Cyclophosphamide 14Lapatinib 13Letrozole 11Carboplatin 11Radiotherapy 10Doxorubicin 10palbociclib 9Therapeutics 9Nivolumab 9Exercise 9Gemcitabine 8Cisplatin 8Blood Specimen Collection 8Tamoxifen 7Bevacizumab 7liposomal doxorubicin 6exemestane 6abemaciclib 6Vinorelbine 6Standard of Care 6Fluorouracil 6atezolizumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × CP protocol × Breast × Clear all
NCT07102940 2026-02-20

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

George Washington University

Phase 2 Not yet recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡